Asthma and chronic obstructive pulmonary disease (COPD) affect more than 300 million people worldwide and together make up a $13.9 billion market. Furthermore, the overall economic impact of these conditions in the seven major pharmaceutical markets in 2000 may have been as high as $52 billion. Decision Resources, Inc., announces the publication of Next-Generation Respiratory Disease Therapeutics: An Analysis of Key Competitor Pipelines, a new DR Report that examines major drug development efforts likely to reach the market by 2005 to treat asthma and COPD. These diseases are discussed together in this report because despite the minimal overlap both in disease symptoms and in the population affected, asthma and COPD require similar treatment and some agents developed for asthma may subsequently be approved for COPD.

(Photo: )

This report examines the near-term pipelines of six respiratory disease market leaders-GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Aventis, Schering-Plough, and Novartis-as well as four companies with promising agents in development. Most of the major developments likely to reach the market by 2005 to treat asthma and COPD are extensions of existing therapeutic categories. However, two or three agents employing new therapeutic principles will reach the market before 2005.

Combination Products Drive Market Growth

The most significant development is the rollout of inhaled agents that combine corticosteroids with long-acting beta2 agonists. Clinical studies have conclusively demonstrated that the concurrent administration of two such drugs provides much superior control of asthma than either agent administered alone. GlaxoSmithKline's Advair/Seretide (fluticasone plus salmeterol) and AstraZeneca's Symbicort (budesonide plus formoterol) are such combination products; both were launched for asthma, but a further boost in sales is expected if these agents prove highly efficacious in treating COPD.

Spiriva-The Launch of a Blockbuster COPD Agent

Boehringer Ingelheim will continue to dominate the market in anticholinergics, the COPD treatment of choice, with the launch of a long- acting agent, tiotropium bromide (Spiriva), whose once-daily administration should greatly improve patient compliance. Boehringer Ingelheim will comarket Spiriva with Pfizer.

In the Pipeline

A number of PDE4 inhibitors are in advanced clinical development for the treatment of COPD and/or asthma. Agents from this class may reach the market by 2005, most notably GlaxoSmithKline's Ariflo (cilomilast) for COPD and Byk Gulden's roflumilast, which has completed Phase II COPD studies and is in Phase III evaluation for asthma. Genentech/Roche and Tanox Biosystems/Novartis's Xolair is another promising product that represents a new approach to asthma treatment that could dramatically alter the treatment paradigm while generating substantial revenues.

Next-Generation Respiratory Disease Therapeutics: An Analysis of Key Competitor Pipelines is a DR Report published by Decision Resources, Inc. This report is available for $4,250.00.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, Inc., +1-781-296-2636,

Gilead's New Antiviral Will Challenge GlaxoSmithKline's Lamivudine for Market Share in the Treatment of Chronic Hepatitis B, According to a Decision Resources Study

View Now